PKAN – Pantothenate kinase-associated neurodegeneration

An updated description of the disease is currently being prepared. Please be patient.

The latest patient-oriented information on NBIA and the individual forms can be found here:

News about PKAN

Here you can find the latest information on the NBIA variant PKAN.

PKAN study with CoA-Z completed in the USA

From 2019 to 2022, Oregon Health & Science University in Portland (USA) conducted a first clinical trial for PKAN patients in the USA with a new drug called "CoA-Z" for the treatment of PKAN. This first part of the study has now been...

read more
CoA Therapeutics press release on Phase 1 study for PKAN

CoA Therapeutics press release on Phase 1 study for PKAN

We hereby issue the following press release from CoA Therapeutics: "CoA Therapeutics and BridgeBio Pharma present data from the Phase 1 study in healthy individuals to support the development of BBP-671 for PKAN and organic acidemia On May 26, 26th...

read more
Survey Helps Prepare Clinical Trial for PKAN Patients

Survey Helps Prepare Clinical Trial for PKAN Patients

The Californian company CoA Therapeutics is currently preparing a clinical trial of a new drug for PKAN patients. In order to make this study as patient-centered as possible, CoA Therapeutics developed a survey last year in which the...

read more
PKAN drug screening at Yale University

PKAN drug screening at Yale University

Since July 2021, a new one-year PKAN research project has been underway at Yale University, New Haven (USA) under the direction of Professor Choukri Ben Mamoun. The project, entitled: "A high-throughput screen for PKAN-revising agents", is being carried out as part of...

read more

Subscribe to our Hoffnungsbaum newsletter!

With our newsletter e-mails you will receive valuable information about NBIA. If you would like to receive additional information on individual NBIA variants or special information for researchers/clinicians in addition to the general newsletter, please click here: Subscribe to additional information

Privacy policy

You have successfully registered!